Omead  Ostadan net worth and biography

Omead Ostadan Biography and Net Worth

COO of Seer
Omead Ostadan is the President and Chief Operating Officer for Seer, as well as a member of our Board of Directors. He was most recently Chief Product and Marketing Officer and a member of Illumina’s executive management team. He joined Illumina in 2007 as Vice President of Marketing and built the company’s marketing organization during a period of tremendous growth and diversification. In 2011 Mr. Ostadan was Senior Vice President of Product Development and in 2015 his role expanded to include the company’s Global Operations and Quality functions. Prior to joining Illumina, Mr. Ostadan was Vice President of Marketing at Solexa from 2005-2007. Before Solexa, Mr. Ostadan held a variety of marketing roles at Applied Biosystems over a nearly 10-year span, where he managed the company’s high throughput sequencing platforms. Mr. Ostadan holds a BS in Biochemistry from the University of California at Davis and an MBA from The Wharton School at the University of Pennsylvania.

What is Omead Ostadan's net worth?

The estimated net worth of Omead Ostadan is at least $722,434.58 as of May 27th, 2022. Mr. Ostadan owns 378,238 shares of Seer stock worth more than $722,435 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Ostadan may own. Learn More about Omead Ostadan's net worth.

How do I contact Omead Ostadan?

The corporate mailing address for Mr. Ostadan and other Seer executives is , , . Seer can also be reached via phone at 650-453-0000 and via email at [email protected]. Learn More on Omead Ostadan's contact information.

Has Omead Ostadan been buying or selling shares of Seer?

Omead Ostadan has not been actively trading shares of Seer during the last ninety days. Most recently, Omead Ostadan sold 4,441 shares of the business's stock in a transaction on Friday, May 27th. The shares were sold at an average price of $8.06, for a transaction totalling $35,794.46. Following the completion of the sale, the chief operating officer now directly owns 378,238 shares of the company's stock, valued at $3,048,598.28. Learn More on Omead Ostadan's trading history.

Who are Seer's active insiders?

Seer's insider roster includes Omid Farokhzad (), David Horn (CFO), and Omead Ostadan (COO). Learn More on Seer's active insiders.

Are insiders buying or selling shares of Seer?

During the last twelve months, Seer insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $98,000.00. During the last twelve months, insiders at the sold shares 5 times. They sold a total of 78,799 shares worth more than $152,501.27. The most recent insider tranaction occured on March, 7th when CEO Omid Farokhzad sold 52,857 shares worth more than $107,299.71. Insiders at Seer own 15.0% of the company. Learn More about insider trades at Seer.

Information on this page was last updated on 3/7/2024.

Omead Ostadan Insider Trading History at Seer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2022Sell4,441$8.06$35,794.46378,238View SEC Filing Icon  
4/20/2022Sell52,042$10.18$529,787.56384,080View SEC Filing Icon  
12/15/2021Sell20,000$23.10$462,000.00View SEC Filing Icon  
11/15/2021Sell20,000$30.50$610,000.00View SEC Filing Icon  
10/15/2021Sell20,000$32.96$659,200.00View SEC Filing Icon  
See Full Table

Omead Ostadan Buying and Selling Activity at Seer

This chart shows Omead Ostadan's buying and selling at Seer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seer Company Overview

Seer logo
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.91
Low: $1.78
High: $1.94

50 Day Range

MA: $1.81
Low: $1.54
High: $2.09

2 Week Range

Now: $1.91
Low: $1.46
High: $5.65

Volume

957,441 shs

Average Volume

472,434 shs

Market Capitalization

$123.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65